Wendy Kane

Partner - Rare Disease, Roche

Wendy Kane

Wendy Kane, Rare Conditions Partner at Roche Products Ltd in the Pipeline Division. She has over 30 years working with and for patients across the NHS, voluntary and pharmaceutical industry sectors. Her experience built from a front-line role treating patients to managing a national public health campaign in the voluntary sector to specialising in building access to rare disease treatments.

She is currently focusing on the 2 rare conditions of Duchenne Muscular Dystrophy and Huntingtons’ Disease and is partnering with the wider rare disease communities and the broader ecosystems which include patients, patient groups, clinicians, payers, and policy influencers with the aim of preparing for access to potential innovative treatments.

Advanced Therapies: Navigating Challenges and Fostering Collaboration for Patient Access

Cell and gene therapies are changing the way we think about and treat rare diseases. We’ll ask “is there adequate service provision, staffing and infrastructure in place to deliver each and every gene therapy safely, effectively and efficiently?”

My three wishes for the future of rare disease are:

1.That all the key stakeholders in the UK are able to collaborate and find the access and service solutions needed so that innovative treatments can be available to patients in a timely manner.

2.There is equity of access across the the 4 nations to the NHS and social care services needed by people with a rare disease and their families.

3.The UK is looked to as a global leader for ATMPs for patients from clinical trials to reimbursed access